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Frequency and implications of HIV superinfection
Andrew D Redd, Thomas C Quinn, Aaron A R Tobian
HIV superinfection occurs when an individual with HIV is infected with a new distinct HIV viral strain. Superinfection 
has been reported throughout the world, and studies have recorded incidence rates of 0–7∙7% per year. Use of next-
generation sequencing has improved detection of superinfection, which can be transmitted by injecting drug use and 
sexual intercourse. Superinfection might have incidence rates comparable to those of initial HIV infection. Clinicians 
should encourage safe sexual and injecting drug use practices for HIV-infected patients because superinfection has 
detrimental eﬀ ects on clinical outcomes and could pose a concern for large-scale antiretroviral treatment plans. The 
occurrence of superinfection has implications for vaccine research, since it seems initial HIV infection is not fully 
protective against a subsequent infection. Additional collaborative research could beneﬁ t care of patients and inform 
future vaccine design.
Introduction
HIV superinfection occurs when an individual with 
HIV becomes infected with a new, phylogenetically distinct 
viral HIV strain. This diﬀ ers from HIV dual infection, 
which is deﬁ ned as being infected with two or more distinct 
viral strains at one point in time. Dual infection can be 
caused by superinfection as well as co-infection, which is 
initial infection with two or more strains. The possibility of 
superinfection was ﬁ rst discovered after the observation of 
co-infection with both HIV-1 and HIV-2, which are 
evolutionarily distinct viral species that share about 42% of 
nucleotide homology in their envelope genes.1–3
Additional evidence for superinfection came from HIV-1 
recombinant forms, which are HIV virions that contain 
separate genomic sections from distinct HIV-1 subtypes. 
HIV-1 is diﬀ erentiated by genetic sequence into nine 
subtypes—A, B, C, D, F, G, H, J, and K, which have been asso-
ciated with diﬀ erent rates of disease progression, viral 
load, detection method assay sensitivity, and distinct 
geographical regions.4,5 HIV-1 virions are diploid and viral 
strains are able to recombine when two distinct subtypes 
infect a single cell. If this new recombinant strain is 
transmitted it can become a circulating recombinant 
form. Roughly 10% of all HIV-1 infections involve re-
combinant viruses, providing further evidence of 
superinfection.6
Although HIV superinfection has been strongly 
suspected for many years, whether individuals were 
infected by two distinct HIV-1 viruses simultaneously 
(co-infection or dual infection), or whether a secondary 
infection occurred after the initial infection (super-
infection), has been diﬃ  cult to distinguish. Insuﬃ  cient 
well documented longitudinal samples and absence of 
sensitive techniques for HIV superinfection detection 
prevented its documentation until 2002.7–9 Under-
standing of both intra-subtype and inter-subtype HIV 
superinfection is not only important for appropriate 
management, but could also provide insights into viral 
evolution and host immune responses to repeat HIV 
challenges before and after superinfection. Such infor-
mation could have substantial implications for HIV 
vaccine development, global public health eﬀ orts, and 
care of patients.
Detection of HIV superinfection
The investigators in initial studies that identiﬁ ed indi-
viduals dually infected with HIV-1 and HIV-2 used 
serological assays that could easily distinguish between 
the two viral species;3 however, this approach cannot 
distinguish between diﬀ erent HIV-1 subtypes or strains. 
The initial cases of HIV superinfection were identiﬁ ed in 
injecting drug users in Thailand by restriction fragment 
analysis on ampliﬁ ed viral sequences from longitudinal 
samples followed by conﬁ rmatory viral sequencing.9 At 
the same time, two separate super infection cases were 
identiﬁ ed in two men who have sex with men who were 
being monitored as part of larger clinical studies after 
they had unexplained spikes in their set-point viral 
loads.7,8 Samples from these individuals before and after 
the spike were subsequently analysed by subtype-speciﬁ c 
PCR ampliﬁ cation7 or direct sequencing8 to conﬁ rm the 
presence of new viral populations. Other groups sub-
sequently used these strategies of screening populations 
for spikes in viral load10–14 or subsequent restriction 
fragment analysis15 followed by direct sequencing to 
identify HIV superinfection.
After these initial studies, three diagnostic strategies 
were used to screen for HIV superinfection in popu-
lations: heteroduplex mobility assays,16–18 multi region 
hybridisation assays,19 and bulk viral sequence analysis20–25 
followed by selective cloning of those samples that 
suggested emergence of new viral variants. Multiregion 
hybridisation assays can identify only inter-subtype 
superinfection. Heteroduplex mobility assays, however, 
can detect samples with greater than 1∙5% genetic 
diﬀ erence but are susceptible to false positives caused by 
insertions or deletions.26 Bulk sequencing can be used to 
examine for changes in the viral population by either 
searching for new phylogenetic species at a later 
timepoint or quantifying the amount of degenerate bases 
in a given sequence. The sensitivity of this strategy relies 
on the likelihood of ampliﬁ cation of the new viral popula-
tion and not only the original strain. Not surprisingly, 
examination of degenerate bases poorly detected minor 
variants at levels of 20% or lower.26 Additionally, all 
these methods need conﬁ rmation with cloning and 
sequencing.27–29 To avoid problems associated with less 
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sensitive screening techniques, a range of populations 
with diﬀ ering risk behaviours were screened for HIV 
superinfection by either single-viral genome ampliﬁ -
cation27,28 or cloning30,31 and then compared for evidence 
of phylogenetically distinct species. The capacity of these 
two approaches to accurately identify superinfection 
depends on the amount of sequences generated for each 
sample.28,29 The sensitivity of all sequence-based assays 
for identiﬁ cation of superinfection also depends on the 
number of viral genomic regions investigated.28 The two 
approaches are therefore prohibitively expen sive and too 
labour-intensive for large-scale studies.29,32
Because of these limitations, we and other researchers 
have designed and veriﬁ ed next-generation-sequencing 
assays that can detect minor variants at 1% or less of the 
total viral population in a high-throughput way.29,33,34 We 
subsequently used this assay to identify HIV super-
infection both in virally discordant couples and in a large 
population of African HIV seroconverters34,35 (ﬁ gure 1). 
Next-generation-sequencing assays allow one to combine 
screening and veriﬁ cation, and can be done in a high-
throughput manner, allowing for the accurate and timely 
assessment of large, at-risk populations or at an individual 
patient level.35 Additionally, these assays can capture more 
viral diversity than an approach based on ampliﬁ cation of 
single-viral genomes at 40% of the cost and with 20% less 
labour.29 Consequently, next-generation-sequencing is 
becoming the assay of choice for detection of super-
infection. Determination of the timing of the 
superinfection events relies on the sampling intervals 
available for the cohorts being examined. However, as 
knowledge improves of the rates of evolution and 
recombination after superinfection, better esti mation of 
the timing of superinfection by use of phylogenetic and 
evolutionary modelling analyses is possible.
Epidemiology
HIV superinfection has been documented in observational 
studies and case reports in the USA8,23,31,36–38 and Canada,39 
Europe,7,10,13,22,40–42 Australia,11 Asia,9,15 and Africa17,20,21,27,28,35,43 
(ﬁ gure 2); although a small study in Brazil did not ﬁ nd 
HIV superinfection when detection methods less sensitive 
than next-generation-sequencing were used.16 The 
widespread observation of superinfection suggests it is a 
substantial problem and has been under-reported.
Superinfection is transmitted in various ways. Two 
of the initial case reports and several observational 
studies23,37,40 were in men who have sex with men.7,8 
Studies in Thailand and the USA have reported super-
infection in intravenous drug users.9,15,31 Additionally, 
many cases of superinfection among female sex workers 
have been reported.17,20,27,28,43 Although ﬁ rst studied in 
high-risk populations, superinfection was recently found 
to occur among a heterosexual population in rural 
Africa.34,35
HIV superinfection incidence rates of 0% to 7∙7% per 
year have been recorded in several case reports and 
population-based studies.23,27,28,43–45 Incidence rates can vary 
sub stantially with population, the frequency of 
antiretroviral drug use, the length of follow-up, and the 
detection methods used. These diﬀ erences in study design 
have led to several studies reporting no superinfection.45–47 
However, a study using next-generation-sequencing 
assays in Uganda found superinfection incidence rates 
comparable to the rate of initial HIV-infection in the same 
area.35 The study also drew attention to the diﬃ  culty of 
comparison between HIV superinfection and HIV 
primary incidence rates in a population because 
individuals with HIV are inherently at a higher-risk than 
the comparison group.35 Results of this and other studies 
done in regions with multiple circulating subtypes have 
shown both inter-subtype and intra-subtype superinfection 
events, and a predisposition to either form is not 
apparent.27,28,34,35,48 Investigators doing future studies 
comparing incidences of superinfection and primary HIV 
should take into account individual risk practices, and 
ensure that the study is powered to identify a diﬀ erence.
Acquisition of superinfection is suspected to have the 
same risk factors as primary infections, such as higher 
numbers of sexual partners,49 non-marital relation-
ships,49,50 limited condom use,51,52 no antiretroviral use,52,53 
Adequate genetic 
distance from 
original strain to 
rule out natural 
genetic drift
Presence of a new 
distinct population 
consisting of 
multiple unique 
viral sequences
Initial infecting viral population
Viral population after two years
Figure 1: Representative phylogenetic tree for identiﬁ cation and conﬁ rmation of HIV superinfection
Phylogenetic tree of consensus viral sequences of a recent seroconversion sample (red) and a follow-up sample 
from 2 years later (blue) showing an inter-subtype superinfection event  with a selection of subtype reference and 
random sequences from an individual in Uganda shown (black). The diagnostic requirements for superinfection 
are indicated.
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and absence of male circumcision.54,55 However, risk 
factors have not been clearly deﬁ ned because of the small 
number of cases studied. Future research is crucial to 
understand better the frequency and risk of super-
infection on a population level.
A historical hypothesis that HIV superinfection most 
commonly occurs during the initial stage of primary 
infection because of reduced immunity was initially 
supported by many studies and case reports.9,12,23,56 The 
apparent close timing of the primary infection and 
superinfection, however, are probably due to the 
convenient sampling techniques. Time to superinfection 
has been reviewed,56 and it can occur more than 2 years 
after primary infection.7,8,13 Determination of whether a 
predisposition in the timing of HIV superinfection exists 
is important to our understanding of the role an 
individual’s immune system has in protecting them from 
a second HIV challenge.
Transmission and the global pandemic
Modelling studies have been undertaken to estimate the 
eﬀ ect of HIV superinfection on recombination.57,58 These 
models suggest that super infection was probably a pivotal 
component in creation and maintenance of recombination 
rates within a com munity; however, these models relied 
on many epidemiological assumptions that need to be 
clariﬁ ed before the accurate eﬀ ect of superinfection on 
the global pandemic can be ascertained.
One such assumption is how often HIV superinfection 
leads to transmission to partners who are not infected, 
and whether the original, superinfecting, or a 
recombinant strain is transmitted (ﬁ gure 3). Although 
no study has yet addressed this question directly, several 
investigators have attempted to ﬁ nd linked 
superinfection events by examining virally discordant 
HIV-infected partners.21,30,34,37 In two such couples, the 
HIV superinfection events were linked as veriﬁ ed by 
clonal sequencing21 or in-depth recombination analysis.37 
In view of the rarity of these linked cases, groups 
investigating superinfection-induced transmission 
events should combine their ﬁ ndings as much as 
possible.
Pathogenesis
Initial studies of HIV superinfection used distinct 
spikes in HIV viral load to identify new cases; the fact 
that in most cases superinfection will cause this type of 
response is generally accepted (ﬁ gure 4).7,8,56,59 Whether 
super infection results in a sustained rise in set-point 
viral load, however, is unclear. Results of several studies 
have shown an increased viral load in individuals with 
evidence of dual infection or superinfection,10,23,60,61 
although others showed no such link.40 In two studies in 
which conﬁ rmed superinfection events in Africa were 
examined, no consistent pattern of increased viral load 
set-point was found, even though set-point viral load 
increased by 0∙5 log in seven of the 16 cases iden-
tiﬁ ed.27,28,35 Taken together, these data suggest that 
superinfection could lead to an increased viral load on a 
population level, but that it is not a necessary phenotype.
Figure 2: Worldwide cases of documented HIV-superinfection
Except for a small study in Brazil which did not ﬁ nd HIV superinfection when using less sensitive detection methods than next generation sequencing, all countries in 
white as reported in the medical literature have not been investigated for superinfection. Text indicates modes of transmission or risk groups and number of cases 
versus number screened by country for all observational studies in which HIV superinfection was detected. HS=heterosexual. FSW=female sex workers. MSM=men 
who have sex with men. IDU=injecting drug users.
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Although viral load is a strong predictor of HIV disease 
progression, the eﬀ ect of superinfection is unclear.56 
Many studies have linked superinfection and dual infec-
tions to more rapid CD4 cell loss,19,23,56,62 although others 
have not shown an eﬀ ect.61 One caveat is that the number 
of superinfection cases in these studies is small, so they 
are often grouped together with dual infections. Gottlieb 
and colleagues36 described a case of a patient with 
superinfection who had a highly pathogenic dual-tropic 
HIV strain (using both CCR5 and CXCR4 as coreceptors 
for cellular entry), which led to rapid disease progression. 
In addition, others have docu mented cases of HIV 
superinfection causing either long-term non-progressors 
or elite controllers to progress to disease.41,63 However, 
another study docu mented superinfection in an elite 
controller who regained some control of the infection.64 
A mathematical model predicted that only superinfection 
by a more so-called ﬁ t strain would result in faster 
disease progression.65 These data suggest that the full 
extent and potency of the detrimental eﬀ ects of 
superinfection remain unclear and might depend on 
several viral and host factors.
Immunology
The immunological aspects of superinfection are 
inherently related to HIV vaccinology,59 and the initial 
studies that described superinfection acknowledged this 
fact.7–9 These studies, and others in various populations, 
provide a sobering fact for HIV vaccine design—that 
initial HIV infection and the host’s subsequent immune 
responses are not fully protective against a new HIV 
challenge. However, these ﬁ ndings also give investigators 
unique populations and novel research paths to identify 
which components of the natural HIV immune response 
could be protective against HIV superinfection, which 
components are not protective, and what happens to the 
immune response after a second successful HIV viral 
challenge.
Initially, Altfeld and colleagues8 showed in a case report 
that superinfection occurred even in the presence of a 
broad HIV-speciﬁ c cytotoxic T-lymphocyte response.8 This 
absence of a protective eﬀ ect for cytotoxic T-lymphocyte 
responses has since been conﬁ rmed in several studies.61,66,67 
Neutral ising antibodies (NAb) have long been thought to 
be an essential component of any successful protective 
HIV vaccine. Examination of NAb response before HIV 
superinfection in case-control studies has produced mixed 
results (ﬁ gure 4). Smith and colleagues68 observed that 
individuals before a superinfection event seemed not to 
have a NAb response. This observation was supported by 
another small study of heterosexual couples in Zambia 
that found individuals with HIV superinfection had a 
delayed NAb response to their autologous virus before 
superinfection;69 however, results of a larger case-control 
study of Kenyan female bar workers showed no sig niﬁ cant 
diﬀ erence in NAb strength before super infection.48 This 
research group also reported that antibody-dependent cell-
mediated viral inhibition was not associated with 
protection from superinfection.70 Although the protective 
eﬀ ect of NAb towards HIV superinfection remains unclear, 
results of several studies have shown superinfection 
boosted the NAb response after super infection.48,68,69 The 
extent of this boost varies between cases, but seems to 
increase the potency of the NAb response, as measured by 
the plasma titre needed for neutralisation, as well as the 
breadth.48 However, whether this level of NAb is protective 
against challenge from a third phylogenetically distinct 
strain of HIV is unknown.
Since HIV infection damages the host immune sys-
tem, aspects of the anti-HIV immune response that are 
not fully protective against HIV superinfection might 
still protect against initial infection if recreated by a 
vaccine in the context of a healthy immune system. The 
underlying immunological health of patients examined 
for protection against superinfection should therefore be 
taken into account during study analysis.
One additional diﬃ  culty with study of the eﬀ ects of HIV 
superinfection on the host immune response is that cases 
are diﬃ  cult to identify in large enough numbers to make 
in-depth immunological analyses possible. In addition, 
longitudinal samples of a wide enough range of specimen 
types (peripheral blood mononuclear cells, mucosal 
excretions, serum, etc) to fully examine the host immune 
system are extremely rare. Therefore, for our understanding 
of the association between superinfection and host 
immunity to continue to expand, physicians and 
researchers examining this topic should work cooperatively 
with equivalent laboratory and clinical practices, so that 
studies can be easily compared and combined.
Implications for clinical care
Superinfection has implications for the clinical care of 
people with HIV. The risk of transmission of super-
infection is greater among people with HIV who do not 
use safe sexual practices, and superinfection can lead to 
Initial infection
Original
strain
Superinfecting
strain
Recombinant or
dual infection
Superinfection
TransmissionOriginal viral strain
New viral strain
New recombinant strain
Initially HIV-negative
Figure 3: Hypothetical HIV superinfection transmission pattern
A sequence of a typical heterosexual sexual network involving initial transmission with an original viral strain 
followed by superinfection with a new viral strain. The sequence can result in the newly superinfected partner 
transmitting one or both of their two strains or a new recombinant strain to a subsequent partner. Although this 
demonstrates a heterosexual pattern, a similar pattern would be anticipated for men who have sex with men and 
intravenous drug users.
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increased viral load and disease progression.23,27,35 Thus, 
encouragement of safe sexual and injection practices 
is important, irrespective of HIV infection status. This 
includes counselling of patients with HIV about the risk 
of superinfection and encouragement of monogamous 
relationships, and use of condoms and clean needles. In a 
study of attitudes to HIV superinfection among men who 
had heard of the disease, 135 (82%) of 165 believed that 
superinfection could be damaging to their health and 
122 (74%) of 165 practiced safer sexual practices because of 
concern about it.71 The most important aspect for men in 
this study in improvement of safer sexual practices was 
learning about the negative health consequences of 
superinfection; therefore, if counselling is done correctly, 
it could have a substantial positive eﬀ ect on risk reduction. 
We therefore believe that clinicians and other health-care 
providers should counsel and give people with HIV 
information about the possible detrimental eﬀ ects of 
superinfection as a component of their continuing care.
Antiretroviral therapy is highly eﬀ ective at disrupting 
and in many cases reversing the detrimental clinical 
eﬀ ects of HIV infection. As use of antiretrovirals 
worldwide increases one of the biggest concerns about 
super infecton is the transmission of drug-resistant 
strains, or susceptible strains masking HIV-resistant 
strains. Indi viduals with resistant strains can acquire a 
susceptible strain,12 and those with a susceptible strain can 
acquire a resistant virus.39,72 Because of this negative eﬀ ect 
on treatment, clinicians should be aware of the risk of 
superinfection, and examine individuals with HIV who 
present with a substantial spike in their viral load or a 
drop in CD4 count for emergence of a new resistant strain. 
Standard HIV resistance testing soon after one of these 
events will probably detect the resistance proﬁ le of this 
secondary strain, since the strain is most likely rapidly 
replicating; however, ultra-deep sequencing technologies, 
which are becoming cheaper and easier, might soon 
become more clinically available for the routine detection 
of super infection and acquired resistance.
HIV transmission is directly related to viral load and is 
rare among patients with loads less than 1500 copies 
per mL.73 Randomised controlled trial data also conﬁ rmed 
that antiretrovirals substantially reduce HIV trans-
mission.53 The eﬀ ect of treatment on superinfection 
reduction has not been recorded by a randomised trial; 
however, most cases of superinfection have occurred 
before drug initiation or during treatment interruption. 
In one study of 14 high-risk HIV-seroconcordant couples 
who were treated with antiretrovirals, no cases of 
superinfection were documented.47 The advent of 
increased antiretrovirals use at earlier timepoints will 
also hopefully reduce incidence of superinfection, but 
further research is needed.
Future research questions and important issues
The observation and subsequent description of HIV 
superinfection can be viewed as either a setback or an 
advancement of HIV research, depending on the point of 
view. The scale of the eﬀ ect that superinfection will have 
on future HIV research is mostly unknown, and will rely 
on the ability of inves tigators to more fully answer some 
important funda mental biological questions. What is the 
eﬀ ect of superinfection on disease progression, and what 
factors inﬂ uence this (eg, subtype of superinfecting 
strain, timing of superinfection, magnitude of viral load 
change)? Can a robust NAb response protect individuals 
from superinfection, and what level of response is 
needed for this protection? What aspects of the immune 
response change after superinfection, and does this 
prevent a possible subsequent superinfection event? Are 
some individuals more susceptible to or protected from 
superinfection (eg, circumcised vs uncircumcised men, 
HLA-B57+ individuals)? What are the risk factors for 
superinfection, and do these diﬀ er from primary HIV-
infection? Does superinfection increase the likelihood of 
transmitting to a partner, and what is the role of 
superinfection in transmission chains? Does 
antiretroviral therapy decrease superinfection and any 
subsequent transmission events?
The diﬃ  culty of identiﬁ cation of superinfection cases, 
and the labour and cost associated with screening large 
populations for these events, mean collaboration of 
researchers and clinicians will be essential to address 
these and other interesting questions. Therefore, when 
researchers use new and more technologically advanced 
diagnostic and experimental assays to examine super-
infection, the strengths and limitations of every tech-
nique should be clearly stated and the sample population 
carefully described.
Figure 4: Representative clinical and virological aspects of HIV superinfection
Putative representative graph indicating the HIV viral load, CD4 cell count, CD8 cytotoxic T-lymphocyte response, 
and anti-HIV neutralising antibody (NAb) response of a typical case. The spike shown in viral load after 
superinfection is similar to what is found during acute infection, which might or might not result in a higher 
set-point viral load. An increase in NAb response is also shown after superinfection.
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Conclusions
HIV superinfection has a potentially deleterious 
pathogenic eﬀ ect on individuals with the infection. 
Results of initial studies have suggested that clinicians 
could lower the incidence of risky behaviours by simply 
informing patients of the potential eﬀ ects of super-
infection. Information about the risks and prevention 
should therefore be included as part of any comprehensive 
counselling strategy. Over the past decade, HIV vaccine 
research has focused on the improvement of 
understanding how some people with HIV naturally 
control their initial infection, and investigators have 
attempted to replicate this state in healthy individuals to 
provide some level of protection against future virus 
challenge. The prevalence of superinfection reported 
around the world suggests that this approach will probably 
not succeed, and vaccine strategies attempting this 
approach have been largely unsuccessful. Con versely, the 
study of HIV superinfection allows exam ination of the 
aspects of the naturally occurring immune response that 
might, or might not, be important for protection against 
subsequent viral challenge in a natural environment. 
These insights will help the develop ment of a more 
targeted HIV vaccine research agenda by suggesting 
promising aims for study, and, crucially, ruling out aspects 
of the immune response that do not seem to be protective.
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Search strategy and selection criteria
We searched PubMed for papers that were published in 
English between Jan 1, 1980 and Dec 1, 2012. The keyword 
search terms used included “HIV superinfection”[All Fields] 
OR “HIV dual infection”[All Fields] OR ((“hiv”[MeSH Terms] 
OR “hiv”[All Fields]) AND double[All Fields] AND 
(“infection”[MeSH Terms] OR “infection”[All Fields] OR 
“communicable diseases”[MeSH Terms] OR 
(“communicable”[All Fields] AND “diseases”[All Fields]) OR 
“communicable diseases”[All Fields])) OR “HIV-1 
superinfection”[All Fields] OR “HIV-1 dual infection”[All 
Fields] OR “HIV-1 double infection”[All Fields] OR “HIV 
reinfection” [All Fields] OR “HIV-1 re-infection” [All Fields]. 
Articles of relevance from reference lists were also 
incorporated. Only studies of original research or case reports 
of distinct HIV infection were included.
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